Targeted Disease(s):
Non-Cystic Fibrosis Bronchiectasis
Purpose of Study:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis
Study Dates:
November 10, 2020 - April 1, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Insmed Incorporated
Sponsors:
Insmed Incorporated
Contact:
Name: PatientWing
Phone: (213) 549-2979
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT04594369